【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2026次   下载 1706 本文二维码信息
码上扫一扫!
连续性与间歇性血液滤过治疗Ⅰ型心肾综合征的临床研究
高月花,那宇*,韦加美,李爽,汪艳,周磊,孙清海,高建军,潘配强,李婷,王孛
0
(解放军306医院肾内科, 北京 100101)
摘要:
目的 对比连续性静脉-静脉血液滤过(continous veno-venous hemofiltration,CVVH)与间歇性血液滤过(intermittent hemofiltration, IHF)治疗对Ⅰ型心肾综合征患者血流动力学及临床预后的影响。方法 收集2008年5月至2011年6月在我院接受CVVH或IHF治疗的Ⅰ型心肾综合征患者资料,共34例,19例为CVVH治疗,15例为IHF治疗。分析患者一般资料,治疗前后心率、血压变化及透析治疗后28 d生存情况。结果 CVVH与IHF组患者治疗前后心率、舒张压差异均无统计学意义(P>0.05);两组患者治疗前收缩压差异也无统计学意义(P>0.05),但IHF组治疗后收缩压低于CVVH组(P<0.05);治疗后48 h,CVVH与IHF组最大平均压、血压波动差异均无统计学意义(P>0.05),但IHF组最低平均压低于CVVH组(P<0.05)。CVVH组和IHF组患者心功能改善情况、28 d病死率差异均无统计学意义(P>0.05)。多因素分析显示,APACHE Ⅱ分值是患者死亡的主要影响因素;APACHE Ⅱ分值、单位时间内净超滤量是最低平均压的主要影响因素。结论 与IHF相比,CVVH治疗Ⅰ型心肾综合征未能明显降低病死率。Ⅰ型心肾综合征患者生存和血流动力学的主要影响因素均是患者病情的严重程度。
关键词:  连续性静脉-静脉血液滤过  间歇性血液滤过  心肾综合征
DOI:10.3724/SP.J.1008.2012.00742
投稿时间:2012-03-22修订日期:2012-06-18
基金项目:全军医药卫生“十一五”计划专项课题(10MA020).
Continuous veno-venous hemofiltration and intermittent hemofiltration in treatment of type 1 cardiorenal syndrome: a clinical research
GAO Yue-hua,NA Yu*,WEI Jia-mei,LI Shuang,WANG Yan,ZHOU Lei,SUN Qing-hai,GAO Jian-jun,PAN Pei-qiang,LI Ting,WANG Bei
(Department of Nephrology, No. 306 Hospital of PLA, Beijing 100101, China
*Corresponding author.)
Abstract:
ObjectiveTo compare the effects of continuous veno-venous hemofiltration(CVVH)and intermittent hemofiltration (IHF) on the hemodynamics and clinical outcomes of patients with type 1 cardiorenal syndrome.MethodsFrom May 2008 to June 2011, 34 patients diagnosed with type 1 cardiorenal syndrome were admitted to our hospital and received CVVH(19 cases) or IHF (15 cases) . The general data, acute hemodynamic changes before and after hemofiltration and clinical outcomes at 28 days after hemofiltration were evaluated. ResultsThere were no significant differences in the heart rates, diastolic blood pressure between the two groups before and after hemofiltration (P>0.05) . The systolic pressure was similar between the two groups before hemofiltration (P>0.05), but that in the IHF group was significantly lower than that in the CVVH group after hemofiltration (P<0.05). No significant difference was found in the maximal mean pressure or blood pressure changes between the two groups at 48 h after hemofiltration(P>0.05), but the minimal mean pressure in IHF group was significantly lower than that in the CVVH group (P<0.05). The improvement of cardiac function and the mortality rates at 28 d after hemofiltration were not significantly different between the two groups(P>0.05). Multivariate analysis suggested that APACHE Ⅱ was the main influence factor of 28-day mortality of patients, and APACHE Ⅱ and net ultrafiltration were the main influence factor of the minimal mean pressure. ConclusionCompared with IHF, CVVH fails to greatly reduce the mortality of patients with type 1 cardiorenal syndrome. The severity of the disease is the main influence factor for the hemodynamic changes and the 28-day mortality of patients with type 1 cardiorenal syndrome.
Key words:  continous veno-venous hemofiltration  intermittent hemofiltration  cardiorenal syndrome